Chaoju Eye Care Holdings Full Year 2024 Earnings: Misses Expectations

Chaoju Eye Care Holdings (HKG:2219) Full Year 2024 Results

Key Financial Results

• Revenue: CN¥1.41b (up 2.6% from FY 2023).
• Net income: CN¥195.1m (down 15% from FY 2023).
• Profit margin: 14% (down from 17% in FY 2023). The decrease in margin was driven by higher expenses.
• EPS: CN¥0.28 (down from CN¥0.33 in FY 2023).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Chaoju Eye Care Holdings Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 8.2%. Earnings per share (EPS) also missed analyst estimates by 21%.

The primary driver behind last 12 months revenue was the Consumer Ophthalmic Services segment contributing a total revenue of CN¥706.4m (50% of total revenue). Notably, cost of sales worth CN¥794.2m amounted to 57% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to CN¥239.6m (58% of total expenses). Explore how 2219's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 17% p.a. on average during the next 2 years, compared to a 7.4% growth forecast for the Healthcare industry in Hong Kong.

Performance of the Hong Kong Healthcare industry.

The company's shares are down 16% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. See our latest analysis on Chaoju Eye Care Holdings' balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.